Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications.

Nonalcoholic steatohepatitis (NASH). With this type of fatty liver disease, you’ll have fat in your liver, inflammation, and liver cell damage. This can lead to cirrhosis (liver scarring ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Experts warn that fatty liver disease (FLD) is becoming an epidemic in India, driven by genetics and lifestyle. With a ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic ...